# BA3071

Source: https://onco.cc/drugs/ba3071/  
OnCo record `ba3071` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BA3071 is an experimental monoclonal antibody from BioAtla in phase 2 trials for non-small-cell lung cancer and melanoma, aimed at CTLA-4.

## Summary

BA3071 is a monoclonal antibody developed by BioAtla. Its target is CTLA-4 (the sponsor names CTLA-4). The sponsor states: A Conditionally Active Biologic (CAB-C) anti-CTLA-4 antibody engineered to bind and block CTLA-4 preferentially within the tumour microenvironment (rather than systemically), activating T cells locally to reduce systemic toxicity. ClinicalTrials.gov describes the intervention as: Conditionally active biologic (CAB) antibody that binds to CTLA-4. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer and melanoma. The largest, NCT05180799, plans to enrol 320 participants with primary completion was scheduled for 2025-03-19 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: monoclonal antibody
- Mechanism: A Conditionally Active Biologic (CAB-C) anti-CTLA-4 antibody engineered to bind and block CTLA-4 preferentially within the tumour microenvironment (rather than systemically), activating T cells locally to reduce systemic toxicity.

## Sources

- ClinicalTrials.gov: trials of BA3071: https://clinicaltrials.gov/search?intr=BA3071
- Sponsor pipeline page: https://www.bioatla.com/cab-portfolio/

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [CTLA-4](https://onco.cc/targets/ctla4/)
- companies: [BioAtla](https://onco.cc/companies/bioatla/)
- trials: [A Phase 1/2 Study of BA3071 in Patients With Solid Tumors](https://onco.cc/trials/nct05180799/)

---
JSON: https://onco.cc/api/v1/entities/ba3071.json